Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

ONGENTYS (opicapone) for the Treatment of Parkinson’s Disease

Drug (Brand/Generic)

ONGENTYS® (opicapone)

Developer

Neurocrine Biosciences

Product Description

Oral capsules

Therapy Class

Catechol-O-methyltransferase (COMT) inhibitor

Current Indication

Parkinson's disease

Market Sector

Central nervous system (CNS)

Development Status

Approved in the US, Europe and Canada
Expand
Close
Close
Close

Go Top